DrAshley Brown

Translational development of new agents alone and in combination to combat Gram-negative pathogens important in Ventilator- Associated Bacterial Pneumonia: Leveraging the Gram-negative toolbox that is

Testing of SARS-CoV2 inhibitors in cell-based infection assays

Rapid Inactivation of SARS-CoV-2 Variants by Puradigm Technology

Are We Truly Protected- Assessment of Immunity Protection Against Mutating COVID-19 Strains & Assay Development

Evaluation of air purification methods for SARS-CoV-2

COVID-19: Monoclonal Antibody Production

Evaluation of escape mutants to ADG20 against SARS-CoV-2 virus using a hollow fiber infection model system

COVID-19: Sx and other mixes of acids and esters to inactivate SARS-CoV-2 and other viruses

Rapid Inactivation of SARS-CoV-2 by Puradigm Technology

COVID19: Inactivation of SARS-CoV-2 by Puradigm Technology

COVID-19: Antiviral Evaluations for Four Compounds against a Human SARS-CoV-2 Isolate

SBIR: Microneedle Delivery of Zanamivir for Treatment of Influenza Infections

CZ-02 pharmacodynamic studies, A New Class of Antibiotics Selectively Inhibiting Bacterial Protein Synthesis

Identification of antiviral therapies for the treatment of Zika virus using existing drugs

Prevalence and mechanism of baseline Nitroimidazole resistance in MDR and XDR TB

Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa

Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models